Allergy

Older people adhering to the antioxidant-rich diet were less likely die from cardiovascular conditions when exposed to greater ambient air pollution.

All told, 41.5% of those receiving dupilumab every 2 weeks and 38% of those receiving it every 4 weeks achieved an Eczema Area and Severity Index score ≥75%, compared with 8% of those receiving placebo.

At the Clinical immunology Society Annual Meeting in Toronto on April 27-28, Prometic presented data from its pivotal Intravenous Immunoglobin (IVIG) Phase 3 clinical trial.

Oral immunotherapy appears to be particularly promising and has strong potential for anaphylaxis protection when administered by protocol.

After a thorough analysis of all controlled studies, no strong clinically significant evidence was observed for any individual or multicomponent intervention.

While advances have been made in understanding EoE, most studies have been descriptive and our understanding of the etiology of EoE remains elusive.

Mepolizumab reduced Asthma Control Questionnaire scores from baseline by –1.45 in patients that had uncontrolled asthma with omalizumab.

KIT inhibition with imatinib reduced mast cells in patients with severe asthma in a proof-of-concept trial, but is the treatment feasible for the future?

While multi-faceted approaches have been shown to be cost-effective, realistically they can be costly and impractical to implement. But environmental and educational interventions hold some promise.

The president of the American College of Allergy, Asthma & Immunology talked the session's future impact, upcoming therapies, and what his favorite lectures were.

African Americans have a 2.5-fold greater chance for developing asthma and a 1.8-fold greater chance for developing eczema, but ironically have a lower chance of receiving a FA diagnosis compared to white children.